Trump Administration Seeks Domestic Production of 86 Essential Drugs

The Trump administration is working to reduce reliance on foreign pharmaceutical production by moving the manufacturing of 86 essential generic medications to the United States. These drugs are currently produced primarily abroad, creating a dependency on international supply chains for critical medicine.

To implement this shift, the United States Office of Management and Budget will solicit proposals from pharmaceutical companies. The government seeks input from drugmakers on how to establish the necessary domestic manufacturing capabilities to ensure these essential medicines are produced within U.S. borders.